The Interplay of Circulating Tumor DNA and Chromatin Modification, Therapeutic Resistance, and Metastasis

Overview

Journal Mol Cancer

Publisher Biomed Central

Specialties Molecular Biology
Oncology

Date 2019 Mar 10

PMID 30849971

Citations 35

Authors

Lei Zhang

Yiyi Liang

Shifu Li

Fanyuan Zeng

Yongan Meng

Ziwei Chen

Shuang Liu

Yongguang Tao

Fenglei Yu

Affiliations

Soon will be listed here.

Abstract

Peripheral circulating free DNA (cfDNA) is DNA that is detected in plasma or serum fluid with a cell-free status. For cancer patients, cfDNA not only originates from apoptotic cells but also from necrotic tumor cells and disseminated tumor cells that have escaped into the blood during epithelial-mesenchymal transition. Additionally, cfDNA derived from tumors, also known as circulating tumor DNA (ctDNA), carries tumor-associated genetic and epigenetic changes in cancer patients, which makes ctDNA a potential biomarker for the early diagnosis of tumors, monitory and therapeutic evaluations, and prognostic assessments, among others, for various kinds of cancer. Moreover, analyses of cfDNA chromatin modifications can reflect the heterogeneity of tumors and have potential for predicting tumor drug resistance.

Citing Articles

Advances and challenges in the use of liquid biopsy in gynaecological oncology.

Zhang Y, Tian L Heliyon. 2024; 10(20):e39148.

PMID: 39492906 PMC: 11530831. DOI: 10.1016/j.heliyon.2024.e39148.

Phenotyping Tumor Heterogeneity through Proteogenomics: Study Models and Challenges.

Piana D, Iavarone F, De Paolis E, Daniele G, Parisella F, Minucci A Int J Mol Sci. 2024; 25(16).

PMID: 39201516 PMC: 11354793. DOI: 10.3390/ijms25168830.

Phage Biosensor for the Classification of Metastatic Urological Cancers from Urine.

Juusti V, Rannikko A, Laurila A, Sundvall M, Hanninen P, Kulpakko J Life (Basel). 2024; 14(5).

PMID: 38792621 PMC: 11122065. DOI: 10.3390/life14050600.

Unveiling the genetic and epigenetic landscape of colorectal cancer: new insights into pathogenic pathways.

Postwala H, Shah Y, Parekh P, Chorawala M Med Oncol. 2023; 40(11):334.

PMID: 37855910 DOI: 10.1007/s12032-023-02201-8.

Simple and Ultrasensitive Detection of Glioma-Related ctDNAs in Mice Serum by SERS-Based Catalytic Hairpin Assembly Signal Amplification Coupled with Magnetic Aggregation.

Wang Y, Yang Y, Cao X, Liu Z, Chen B, Du Q Int J Nanomedicine. 2023; 18:3211-3230.

PMID: 37337576 PMC: 10276994. DOI: 10.2147/IJN.S410080.

References

Berridge M, Dong L, Neuzil J . Mitochondrial DNA in Tumor Initiation, Progression, and Metastasis: Role of Horizontal mtDNA Transfer. Cancer Res. 2015; 75(16):3203-8. DOI: 10.1158/0008-5472.CAN-15-0859. View

Faloppi L, Del Prete M, Casadei Gardini A, Santini D, Silvestris N, Bianconi M . The correlation between LDH serum levels and clinical outcome in advanced biliary tract cancer patients treated with first line chemotherapy. Sci Rep. 2016; 6:24136. PMC: 4827080. DOI: 10.1038/srep24136. View

Li W, Zhang X, Lu X, You L, Song Y, Luo Z . 5-Hydroxymethylcytosine signatures in circulating cell-free DNA as diagnostic biomarkers for human cancers. Cell Res. 2017; 27(10):1243-1257. PMC: 5630683. DOI: 10.1038/cr.2017.121. View

Carneiro B, Pamarthy S, Shah A, Sagar V, Unno K, Han H . Anaplastic Lymphoma Kinase Mutation ( F1174C) in Small Cell Carcinoma of the Prostate and Molecular Response to Alectinib. Clin Cancer Res. 2018; 24(12):2732-2739. PMC: 6715284. DOI: 10.1158/1078-0432.CCR-18-0332. View

Shaw J, Guttery D, Hills A, Fernandez-Garcia D, Page K, Rosales B . Mutation Analysis of Cell-Free DNA and Single Circulating Tumor Cells in Metastatic Breast Cancer Patients with High Circulating Tumor Cell Counts. Clin Cancer Res. 2016; 23(1):88-96. PMC: 6241844. DOI: 10.1158/1078-0432.CCR-16-0825. View

Kwak E, Ahronian L, Siravegna G, Mussolin B, Borger D, Godfrey J . Molecular Heterogeneity and Receptor Coamplification Drive Resistance to Targeted Therapy in MET-Amplified Esophagogastric Cancer. Cancer Discov. 2015; 5(12):1271-81. PMC: 4670804. DOI: 10.1158/2159-8290.CD-15-0748. View

Lo Y, Chan K, Sun H, Chen E, Jiang P, Lun F . Maternal plasma DNA sequencing reveals the genome-wide genetic and mutational profile of the fetus. Sci Transl Med. 2010; 2(61):61ra91. DOI: 10.1126/scitranslmed.3001720. View

Lupo M, Guttler R, Geck Z, Tonozzi T, Kammesheidt A, Braunstein G . IS MEASUREMENT OF CIRCULATING TUMOR DNA OF DIAGNOSTIC USE IN PATIENTS WITH THYROID NODULES?. Endocr Pract. 2018; 24(5):453-459. DOI: 10.4158/EP-2017-0213. View

Eng C . Circulating DNA biomarkers: a primer for metastatic colorectal cancer?. Lancet Oncol. 2015; 16(8):878-9. DOI: 10.1016/S1470-2045(15)00061-3. View

10.

Chimonidou M, Strati A, Malamos N, Georgoulias V, Lianidou E . SOX17 promoter methylation in circulating tumor cells and matched cell-free DNA isolated from plasma of patients with breast cancer. Clin Chem. 2012; 59(1):270-9. DOI: 10.1373/clinchem.2012.191551. View

11.

Branco M, Ficz G, Reik W . Uncovering the role of 5-hydroxymethylcytosine in the epigenome. Nat Rev Genet. 2011; 13(1):7-13. DOI: 10.1038/nrg3080. View

12.

Fiala C, Diamandis E . Utility of circulating tumor DNA in cancer diagnostics with emphasis on early detection. BMC Med. 2018; 16(1):166. PMC: 6167864. DOI: 10.1186/s12916-018-1157-9. View

13.

Ossandon M, Agrawal L, Bernhard E, Conley B, Dey S, Divi R . Circulating Tumor DNA Assays in Clinical Cancer Research. J Natl Cancer Inst. 2018; 110(9):929-934. PMC: 6136923. DOI: 10.1093/jnci/djy105. View

14.

Diehl F, Li M, Dressman D, He Y, Shen D, Szabo S . Detection and quantification of mutations in the plasma of patients with colorectal tumors. Proc Natl Acad Sci U S A. 2005; 102(45):16368-73. PMC: 1283450. DOI: 10.1073/pnas.0507904102. View

15.

Jiang P, Chan C, Chan K, Cheng S, Wong J, Wong V . Lengthening and shortening of plasma DNA in hepatocellular carcinoma patients. Proc Natl Acad Sci U S A. 2015; 112(11):E1317-25. PMC: 4372002. DOI: 10.1073/pnas.1500076112. View

16.

Kis O, Kaedbey R, Chow S, Danesh A, Dowar M, Li T . Circulating tumour DNA sequence analysis as an alternative to multiple myeloma bone marrow aspirates. Nat Commun. 2017; 8:15086. PMC: 5437268. DOI: 10.1038/ncomms15086. View

17.

Winther-Larsen A, Demuth C, Fledelius J, Madsen A, Hjorthaug K, Meldgaard P . Correlation between circulating mutant DNA and metabolic tumour burden in advanced non-small cell lung cancer patients. Br J Cancer. 2017; 117(5):704-709. PMC: 5572172. DOI: 10.1038/bjc.2017.215. View

18.

Annala M, Struss W, Warner E, Beja K, Vandekerkhove G, Wong A . Treatment Outcomes and Tumor Loss of Heterozygosity in Germline DNA Repair-deficient Prostate Cancer. Eur Urol. 2017; 72(1):34-42. DOI: 10.1016/j.eururo.2017.02.023. View

19.

Ma W, Jia J, Wang S, Bai W, Yi J, Bai M . The prognostic value of 18F-FDG PET/CT for hepatocellular carcinoma treated with transarterial chemoembolization (TACE). Theranostics. 2014; 4(7):736-44. PMC: 4038755. DOI: 10.7150/thno.8725. View

20.

Huang Z, Wang Z, Bai H, Wu M, An T, Zhao J . The detection of EGFR mutation status in plasma is reproducible and can dynamically predict the efficacy of EGFR-TKI. Thorac Cancer. 2017; 3(4):334-340. DOI: 10.1111/j.1759-7714.2012.00133.x. View